Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback